deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT03034967

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: GlaxoSmithKline

Conditions Pulmonary Disease, Chronic Obstructive
Interventions Danirixin Danirixin matching placebo Rescue medication Standard of care
Updated 22 times since 2017 Last updated: Oct 6, 2020 Started: Apr 25, 2017 Primary completion: Oct 5, 2018 Completion: Oct 5, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03034967, this PHASE2 trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by GlaxoSmithKline, it has been updated 22 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2019 · 13 months · monthly snapshot~Dec 2019 – ~Nov 2020 · 11 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 17 earlier versions

  1. Dec 2019 — Nov 2020 [monthly]

    Completed PHASE2

  2. Nov 2018 — Dec 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  8. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  10. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  11. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  12. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  13. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  14. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  15. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. May 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

  17. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alkmaar, Netherlands , Bacau, Romania , Barcelona, Spain , Berlin, Germany , Birmingham, United States , Breda, Netherlands , Bucharest, Romania , Bucheon-Si, Gyeonggi-Do, South Korea , Clayton, Australia , Cluj-Napoca, Romania and 45 more locations